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Chapter 1 
Introduction 
1.1 Problem Statement 
Salmonella enterica (S. enterica) is a facultative, intracellular, gram-negative 
bacterium that causes serovar-specific disease in a range of hosts. Over 2,500 serovars of 
S. enterica have been identified based on flagellar and lipopolysaccharide (LPS) antigen 
specificity [1]. In the human host, S. enterica serovars may instigate typhoidal as well as 
non-typhoidal illness, both with significant disease prevalence worldwide. Non-typhoidal 
S. enterica is responsible for over 78 million cases of foodborne illnesses and over 59,000 
deaths globally each year [2]. Salmonella enterica serovar Typhi (S. Typhi), the causative 
agent of Typhoid Fever, infects and kills an estimated 20 million and 200,000 individuals 
each year, respectively [3]. S. Typhi is of high clinical relevance in the regions of 
Southern Africa, South-central Asia, and South-eastern Asia, where contamination of 
both food and water sources in developing nations allows Salmonella to spread to new 
hosts [3].  
Upon ingestion of S. Typhi, successful bacteria will persist through the gastric 
barrier of the stomach to reach the small intestine. At this location, S. Typhi crosses the 
intestinal epithelium and is phagocytosed by macrophages to achieve systemic disease 
[4]. Sites commonly infected during systemic salmonellosis include the ileum, liver, 
spleen, bone marrow, and gallbladder [5].  
After resolution of the acute infection, S. Typhi can persist in the gallbladder of 3-
5% of hosts through an asymptomatic chronic carrier state of disease [6]. During chronic 
carriage, S. Typhi forms biofilms—communities of microorganisms that adhere to 
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surfaces and are recalcitrant to immune and antibiotic clearance—on the surface of 
gallstones and the gallbladder epithelium [5, 7]. The process of biofilm formation is 
characterized by sequential events that include initial attachment to a surface, secretion of 
a protective extracellular polymeric substance (EPS), and dispersal of community 
members to the environment [8] (Figure 1). As a human-restricted pathogen, the spread 
of S. Typhi is dependent on this carrier state during which fecal shredding allows bacteria 
to spread to new hosts through contamination of water sources. Thus, the study of S. 
enterica biofilm processes is fundamental to impeding the spread of S. Typhi via chronic 
carriage. 
 
1.2 Hypothesis and Rationale 
The central hypothesis for this thesis is that we can identify and characterize 
compounds with the ability to disrupt the process of S. enterica biofilm formation. 
Utilizing a model organism, Salmonella enterica subspecies enterica serovar 
Typhimurium (S. Typhimurium), this hypothesis was examined with the three following 
aims: 
1. Identification of compounds with anti-biofilm properties. 
2. Examination of the characteristics and activities of identified anti-biofilm 
compounds. 
3. Evaluation of the mechanism of action of anti-biofilm compound T315. 
The discovery and characterization of compounds with the ability to specifically 
inhibit early events in bacterial attachment will aid future studies of Salmonella biofilm 
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formation and is a promising step towards eradication of the Salmonella chronic carriage 
state.  
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Chapter 2 
Materials and Methods 
2.1 Bacterial strains, growth conditions, and kinase inhibitors 
The bacterial strains used in this study were S. Typhimurium 14028s (JSG210), 
Acinetobacter baumannii (JSG3828) and Pseudomonas aeruginosa PAO1 (JSG3906). 
Overnight cultures were grown in LB broth at 37°C with aeration. A 24h rapid 
attachment or temporal addition assay for JSG210 included normalizing to OD600nm=0.8, 
diluting 1:100 into 1:20 TSB, and incubating 24h post drug addition at 30°C in static 
conditions. 24h rapid attachment assays for JSG3828 and JSG3906 included normalizing 
to OD600nm=0.8, diluting 1:100 into LB, and incubating 24h post drug addition at 30°C in 
static conditions. Kinase inhibitor stocks were stored in DMSO at 5 mM. Unless 
otherwise indicated, drugs were administered via a 1:10 dilution of a 50 µM working 
solution of 1% DMSO in PBS, yielding a final drug concentration of 5 µM. 
 
2.2 Rapid Attachment and Temporal Addition Assays 
Biofilm Rapid Attachment Assays were conducted using growth conditions and 
drug concentrations described above with drug added prior to incubation in static 
conditions. 24h post-drug addition, growth was read at OD600 and plates were washed 4 
times in ddH20 to eliminate planktonic cells. Biofilms were heat fixed 1h at 60°C, stained 
with 33% crystal violet solution (6.0 mL PBS, 3.3 mL crystal violet, 333 µL methanol, 
333 µL isopropanol) for 5 min, and released using 33% acetic acid (3.3 mL glacial acetic 
acid, 6.7 mL ddH20) to quantify the stain. Biofilm quantification was performed by 
reading the released dye at OD570. Temporal Addition Assays were conducted using the 
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same conditions and crystal violet technique; however, drug addition was delayed to 1, 3, 
and 6h post-initial incubation, with 15 min on orbital shaker after each addition to ensure 
even drug dispersal.  
 
2.3 Viability Assay 
To determine bactericidal or bacteriostatic properties, S. Typhimurium and A. 
baumannii were grown as previously described (37°C in LB, aerobic conditions) in the 
presence or absence of drug at concentration of 5 or 10 µM. Samples were taken at 0, 2, 
4, 6, 8, 16, and 24h after start of growth, serially diluted, and plated for enumeration. 
 
2.4 EC50 Determination 
The half maximal effective concentration (EC50) was calculated using 
measurements of biofilm inhibition at concentrations of drug from 0.5 to 9 µM (24h at 
30°C) via the Rapid Attachment Assay. Biofilms were quantified using the crystal violet 
stain and dye release technique.  
 
2.5 Generation of T315-Resistant Mutants 
Following 24h exposure of S. Typhimurium to 5 µM T315 at 30°C, cells residing 
within the biofilm were cultured in LB at 37°C and exposed to 5 µM T315 three 
additional times before increasing drug exposure to 7.5 µM and then 10 µM. Additional 
test well replicates were included from which biofilm-residing S. Typhimurium were not 
obtained, and these wells were stained with crystal violet to observe development of 
resistance to T315. Cultures at each stage were stored in 20% glycerol at -20°C. This 
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procedure was performed in triplicate. Resistance to T315 by an isolated mutant obtained 
from biofilms after the 10 µM exposure will be confirmed via the Rapid Attachment 
Assay with 10 µM T315 before submitting mutant gDNA for whole-genome sequencing. 
 
2.6 Direct Pull-Down of T315 and Target 
A polyethylene glycol (PEG) linker and biotin group will be added to T315 via 
click-chemistry. After confirmation that PEGylation and biotinylation of T315 does not 
inhibit anti-biofilm activity, biotinylated T315 will be exposed to a S. Typhimurium 
cellular lysate (obtained via sonication in 50 mM Hepes pH 7.4, 120 mM NaCl, 20 mM 
MgCl2, 0.1% Triton X-100, and 1x commercial complete protease inhibitor cocktail) and 
T315-bound target will be isolated via streptavidin affinity chromatography using the 
Pierce™ Biotinylated Protein Interaction Pull-Down Kit. Target identification will be 
achieved via mass spectrometry. 
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Chapter 3 
Results 
3.1 Identification of kinase inhibitor compounds with anti-biofilm properties 
An initial screen of 90 derivatives of kinase inhibitor compounds against S. 
Typhimurium was performed using 5 µM of compound for 24h at 30°C. Biofilms were 
assessed via crystal violet incorporation. Through this technique, two compounds were 
identified that showed promising anti-biofilm activity: T315 and Cp315. The structure of 
T315, as well as regions of T315 structurally identical to the closely related Cp315 
molecule, are represented in Figure 2. 
Rapid attachment assays performed in triplicate show that T315 and Cp315 at 
concentrations of 5 µM inhibit S. Typhimurium biofilm formation by 59.4% and 58.4%, 
respectively. Previous work with T315 indicate that it has anti-cancer properties, as it has 
been demonstrated to disrupt the PI3K/AKT pathway, which contributes to cancer 
progression [9]. Previously tested prostate and mammary epithelial cells did not show 
cytotoxicity with T315 at concentrations within 1-5 µM [10], and the half-maximal lethal 
dose of T315 against normal T cell and B cell lymphocytes was greater than 10 µM [9]. 
 
3.2 Characterization of the phenotypic effects of promising anti-biofilm agents T315 
and Cp315 
3.2 a. Evaluation of bacteriostatic or bactericidal effects 
Viability assays were used to determine the effects of 5 µM T315 and Cp315 on 
planktonic growth of S. Typhimurium. Over a 24h time-course at 37°C, no substantial 
differences of S. Typhimurium growth was observed between T315 and Cp315 as 
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compared to a no drug control of 1% DMSO in PBS, as shown in Figure 3. These data 
indicate that neither T315 or Cp315 cause a decrease in biofilm formation as a result of 
bacteriostatic or bactericidal effects. 
3.2 b. Characterization of temporal relationships of drug activity 
To better characterize the temporal relationship of drug activity with biofilm 
formation, drug administration was delayed by 1, 3, and 6h post-initial incubation. 
Delaying drug administration allows cells to begin the adherence process before exposure 
to drug and differentiates between preventative and dispersal anti-biofilm effects. As 
shown Figure 4, delayed administration of drugs results in a reduction in their anti-
biofilm activity. At drug administration 6h post-initial incubation (pii), 5 µM T315 
exhibited only a 20% reduction in biofilm formation, as compared to 30% reduction at 3h 
pii, and 42% at 1h pii. Similarly, 5 µM Cp315 exhibited 18% reduction in biofilm 
formation at 6h pii, 25% reduction at 3h pii, and 49% at 1h pii. Thus, even a one-hour 
allowance for Salmonella to begin the biofilm formation processes prior to drug exposure 
reduced the anti-biofilm activity of both compounds as compared to activity quantified in 
rapid attachment assays. 
3.2 c. Determination of half-maximal effective concentration (EC50) of T315 
In order to evaluate the efficiency of T315 activity, the half-maximal effective 
concentration (EC50) was calculated by evaluating anti-biofilm activity at a range of 
concentrations between 0.5 and 9µM. Figure 5 depicts the reduction in S. Typhimurium 
biofilm observed by exposure to T315 at these varying concentrations. The EC50 was 
determined to be equal to 4.61 µM with a 95% confidence interval from 3.13 to 6.78 µM. 
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3.2 d. Characterization of T315 activity against additional gram-negative biofilm-
forming pathogens A. baumannii and P. aeruginosa  
The anti-biofilm activity of T315 towards gram-negative pathogenic biofilm 
forming species A. baumannii and P. aeruginosa was evaluated (Figure 6a). 24h rapid 
attachment assays at 30°C indicate that at a concentration of 10 µM, T315 significantly 
reduces A. baumannii (JSG3828) biofilm formation by an average of 61.2% (p-value < 
0.001). At the 5 µM concentration tested, T315 was not shown to significantly affect 
biofilm formation of P. aeruginosa PAO1 (JSG3906). Enumeration of planktonic growth 
A. baumannii at timepoints over 24h at 37°C indicates that 10 µM T315, while inhibiting 
biofilm formation, does not work through bacteriostatic or bactericidal effects (Figure 
6b). 
3.2 e. Testing of T315 derivative In-T315 for anti-biofilm activity in S. 
Typhimurium 
A compound closely related to T315, termed In-T315, was obtained and evaluated 
for anti-biofilm activity in S. Typhimurium. In-T315 relates to T315 in that the central 
portion of the molecule has been modified to include an additional aromatic ring, 
providing steric bulk to In-T315 while keeping side groups identical to those of T315. 
Assessing biofilm formation with crystal violet staining technique, S. Typhimurium 
biofilm formation 24h at 30°C, we observed that In-T315 exhibited a high level of anti-
biofilm activity at concentrations of 5 and 10 µM.  
Figure 7 illustrates the average biofilm formation observed when JSG210 was 
exposed to both Cp315 and In-T315 at a concentration of 5 µM as well as In-T315 at 10 
µM. At both concentrations tested, Cp315 and InT315 significantly reduced biofilm 
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formation of JSG210. Cp315 exhibited an average of 58.4% inhibition at 5 µM. In-T315 
exhibited an average of 74.8% biofilm inhibition at 5 µM and an average of 83.3% 
biofilm inhibition at 10 µM against JSG210.  
3.2 f. Characterization of T315 anti-biofilm activity against S. Typhimurium surface 
mutants 
 T315 activity against S. Typhimurium surface appendage mutants was 
characterized in hopes of providing insight to T315 functionality. Identification of S. 
Typhimurium mutants used in these studies is included within Table 1 and includes 
strains with reduced expression of curli fimbriae (JSG3736), motility (JSG1547), and 
flagellar appendages FljB (JSG1178) and FliC (JSG1179) in a S. Typhimurium ATCC 
14028s background. The ability of a S. Typhimurium SR11 quadruple fimbriae operon 
mutant (JSG1174) to form biofilms in the presence of T315 was also characterized. 
Strains were exposed to 5 and 10 µM T315 for 24h at 30°C, and biofilm-residing cells 
were stained with crystal violet for quantification of biofilm formation. The level of 
inhibition of biofilm formation observed due to the presence of T315 in the JSG3736, 
JSG1547, JSG1178, and JSG1179 strains is depicted in Figure 8 and can be compared to 
that observed in the JSG210 wild type S. Typhimurium 14028s strain. In these studies, 
JSG1178 exposed to 10 µM T315 experienced an average of 58.9% inhibition of biofilm 
formation while JSG210 displayed 78.4% inhibition at this concentration; this difference 
is statistically significant. JSG1178 is deficient in expression of the S. Typhimurium FljB 
flagellum, suggesting that this appendage may be a target of T315 compound, as the 
compound exhibits reduced biological activity with the absence of this structure. 
JSG1547, JSG3736, and JSG1179 bacterial strains also shown in Figure 8a did not 
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experience a statistically significant change in biofilm inhibition levels compared to the 
JSG210 wild type background strain at any concentration of T315.  
 The anti-biofilm activity of T315 against a S. Typhimurium SR11 quadruple 
fimbriae mutant (JSG1174) was studied at both 5 and 10 µM concentrations. 
Quantification of biofilm formation was achieved after 24h exposure at 30°C through 
crystal violet staining. JSG1174 is deficient in fim, lpfC, pefC, and agfB fimbriae 
structures, and the response of this mutant to T315 was compared to SR11 wild type 
strain JSG1169. No significant difference was observed of T315 anti-biofilm activity 
towards JSG1174 as compared to the JSG1169 wild type background (Figure 8b), 
suggesting that these fimbriae structures are not involved in the mechanism of action of 
T315. 
 
3.3 Evaluation of the mechanism of action of T315 
3.3 a. Generation of a T315-resistant S. Typhimurium isolate 
 To understand the mechanism of action of T315, an attempt was made to generate 
a S. Typhimurium JSG210 isolate that successfully formed biofilms in the presence of the 
compound. Whole-genome sequencing would then be performed on this isolate to 
identify loci altered from the wild-type and thus identify genes and gene products that 
T315 interacts with. Following 24h exposure of S. Typhimurium to 5 µM T315 at 30°C, 
cells residing within the biofilm were obtained and exposed to 5 µM T315 three 
additional times before increasing drug exposure to 7.5 µM and then 10 µM. Additional 
replicate wells were included which were not disturbed by the process of acquiring 
biofilm-residing cells, and these cells were stained with crystal violet to monitor the 
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development of resistance to T315. We did not observe the development of any lasting 
resistance in any of the three biological replicates performed. A transient resistance was 
seen during repetition of the 5 µM drug exposure level, but this phenotype did not persist 
upon an increase to 7.5 µM and subsequently 10 µM; this increase in drug concentration 
from 5 µM was attempted twice.  
3.3 b. Direct Pull Down of T315 and Target 
Attachment of a polyethylene glycol (PEG) linker to T315 was achieved through 
collaboration with the lab of Dr. Jim Fuchs at The Ohio State University via utilization of 
click-chemistry. Synthesized PEG-T315-i included attachment of the PEG linker at the 
site of the piperazine functional group. PEG-T315-i was evaluated for retention or 
reduction of anti-biofilm activity. As depicted in Figure 9b, PEG-T315-i exhibited a loss 
of biological activity. Given this information, we suspect that the (i) site is necessary for 
the biological activity of T315. The polyethylene glycol linker is currently being attached 
at the amide (ii) site of T315. If this location of PEG linkage retains biological activity, a 
biotin marker will be attached, and this molecule will be used for direct pull down of 
JSG210 target and mass spectrometry analysis. 
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Chapter 4 
Discussion 
The S. Typhi chronic carriage state includes the formation of biofilm communities 
on the surface of gallstones in the gall bladder and on the gall bladder epithelium. 
Recalcitrance of biofilms to antibiotic clearance results in difficulty resolving the chronic 
infection. Targeting the biofilm formation process with anti-biofilm therapeutics could be 
used in conjunction with antibiotic agents to eliminate the biofilm reservoir within 
Salmonella carriers. In efforts to identify compounds that counter Salmonella biofilm 
processes, we hypothesized that we can identify and characterize compounds with the 
ability to disrupt the process of S. enterica biofilm formation. This hypothesis was 
examined by (1) the identification of compounds with anti-biofilm properties, (2) the 
examination of the characteristics and activities of identified anti-biofilm compounds and 
(3) the evaluation of the mechanism of action of anti-biofilm compound T315. 
 
4.1 Identification of compounds with anti-biofilm properties 
 Through a screen of 90 derivatives of kinase inhibitor compounds, we identified 
two highly related compounds, T315 and Cp315, which significantly reduced the 
formation of S. Typhimurium biofilms. At the 5 µM concentration used in the 
preliminary screening, T315 and Cp315 inhibited biofilm formation by 59.4% and 
58.4%, respectively. T315 has previously been characterized as an anti-cancer therapeutic 
that targets the PI3K/AKT pathway. Studies indicate that it does not induce host cell 
cytotoxicity in a number of human epithelial cell lines, including prostate and mammary 
epithelial cells as well as T and B lymphocytes.  
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4.2 Examination of the characteristics and activities of identified anti-biofilm 
compounds 
Due to the promising anti-biofilm activity of T315 and Cp315 observed in the 
preliminary screen, the functionality of these compounds were further characterized. 
First, the bacteriostatic or bactericidal activity of the compounds were evaluated by 
exposing S. Typhimurium to 5 µM of each compound and plating for enumeration at 
several timepoints over 24h. Salmonella viable cell density during planktonic growth did 
not appear to be affected by the presence of either T315 or Cp315 in these studies, which 
suggests that the decrease in biofilm formation observed is not a resultant of 
bacteriostatic or bactericidal activity of the compounds. Instead, the compounds interfere 
with a bacterial process specific to the biofilm lifestyle.  
To better understand the temporal relationship between drug addition and 
effectiveness, drug administration was delayed 1, 3, and 6h to allow bacterial cells to 
begin biofilm formation prior to drug exposure. 24h post-exposure, biofilms were 
quantified by crystal violet staining, and we noted that delaying drug exposure impacted 
the effectiveness of both T315 and Cp315 at 5 µM. Delaying T315 addition 1, 3, and 6h 
post-addition of cells resulted in an average of 41.5%, 30.1%, and 19.5% biofilm 
inhibition, respectively, compared to no drug. An identical experiment with Cp315 
resulted in an average of 48.5%, 25.3%, and 17.7% biofilm inhibition, respectively, 
compared to no drug. When added at the same time as initial incubation of Salmonella 
the same concentrations of T315 and Cp315 inhibited biofilm formation by 59.4% and 
58.4%, respectively. When drug administration was delayed to 24h post-initial incubation 
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of cells, when formation of a mature biofilm is underway, less than 3.5% difference 
between biofilm formation with and without the presence of either compound was 
observed (data not shown). These data indicate that both T315 and Cp315 are most 
effective when administered early in the biofilm formation process and are ineffective at 
dispersing a mature biofilm. This suggests that structures involved in the early attachment 
stage of biofilm development, such as the expression of surface appendages, may be 
affected by T315 and Cp315. 
Due to the structural and functional similarities we observed between T315 and 
Cp315, we chose to continue our characterization studies by focusing on T315. Previous 
studies conducted on the anti-cancer properties of T315 described the cytotoxic effects of 
the compound and the compound structure [9, 10]. We determined the half-maximal 
effective concentration of T315 anti-biofilm properties towards S. Typhimurium to be 
4.61 µM with a 95% confidence interval from 3.13 to 6.78 µM. This value is comparable 
to the 5 µM drug concentration we have used throughout these studies. Issues with T315 
solubility in 1x PBS, described in an upcoming section, prevented our EC50 studies from 
exceeding 10 µM, which is a limitation of this work. 
  The effectiveness of T315 anti-biofilm activity towards gram-negative biofilm 
forming pathogens A. baumannii and P. aeruginosa was characterized. 10 µM T315 is 
effective at reducing A. baumannii biofilm formation by an average of 61.2%, and does 
not appear to exhibit bactericidal or bacteriostatic effects on planktonic growth. P. 
aeruginosa biofilms were unaffected by T315 in these studies, which indicates that T315 
is a specific biofilm inhibitor. These data suggest that S. Typhimurium and A. baumannii 
share one or more biofilm-formation processes which are not necessary for P. aeruginosa 
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biofilm formation, and that these processes are targeted by T315 to reduce biofilm 
formation in a species-specific manner. 
A compound closely related to T315, In-T315, was obtained from the lab of 
Ching-Shih Chen for examination of potential anti-biofilm activity. In-T315 side groups 
are identical to those of T315, but has a modified central structure that provides 
additional steric bulk to the molecule. In these studies, exposure of S. Typhimurium to In-
T315 resulted in an average of 74.8% biofilm inhibition at 5 µM and an average of 83.3% 
biofilm inhibition at 10 µM. These data suggest that In-T315 may be a more potent anti-
biofilm agent than T315; however, due to the inherent variability of these studies as a 
result of compound instability in solution these results should be further replicated to 
confirm this finding. 
Due to observations that early addition of drug to bacterial static growth is 
necessary for maximum anti-biofilm activity, we hypothesize that structures on the 
cellular surface involved in early attachment phases of biofilm formation are affected by 
the presence of T315. S. Typhimurium strains with mutations in curli fimbriae (ΔcsgA), 
motility (ΔmotA), FliC flagellum (ΔfliC), FljB flagellum, and fimbriae operons (Δfim 
ΔlpfC ΔpefC ΔagfB) were obtained and T315-induced inhibition of biofilm formation 
was compared to that of appropriate background strains. A significant reduction in anti-
biofilm activity of T315 was observed in the JSG1178 strain, which is deficient in 
expression of the FljB flagella appendage. When exposed to 10 µM T315 for 24h, 
JSG1178 experienced an average of 58.9% inhibition of biofilm formation compared to 
78.4% inhibition of biofilm formation that the background strain JSG210 displayed at 
this concentration. This reduction in efficiency of drug activity suggests that the FljB 
	 19	
structure altered in the JSG1178 strain is involved in the functionality of T315.  The role 
of FljB in S. Typhimurium biofilm formation is inconclusive, which complicates this 
analysis. FljB and FliC, S. Typhimurium flagellar filament structures, are controlled by 
an expression switch. Studies conducted comparing S. Typhimurium attachment to 
cholesterol-coated surfaces conclude that FliC, but not FljB, promote biofilm formation 
[11], while studies on polystyrene at 37°C concluded that the absence of both FliC and 
FljB is beneficial to biofilm formation [12]. In this work, the level of biofilm formation 
between JSG210 and JSG1178 without drug is comparable, while the FliC- FljB+ 
JSG1179 strain was hindered in biofilm formation by an average of 45% compared to 
background JSG210 (data not shown). Since the loss of FljB did not produce a biofilm-
deficient strain, and JSG1179 was attenuated in biofilm formation, one possible 
hypothesis is that both FliC and FljB play a positive role in biofilm formation, but FliC to 
a greater extent. The JSG1178 FljB- FliC+ strain maintains effective biofilm formation 
because of its FliC expression. If T315 is binding directly to the FljB filament in S. 
Typhimurium to hinder biofilm formation processes, this may be occurring 
intracellularly, limiting FljB export and flagellar synthesis, at the cellular surface to coat 
existing FljB flagella, or both. None of the remaining above-mentioned S. Typhimurium 
surface appendage mutants experienced a significant difference in T315-induced anti-
biofilm activity compared to appropriate background strains. These studies may be 
expanded by evaluating efficiency of T315 activity towards additional S. Typhimurium 
mutants, such as those with altered lipopolysaccharide expression, and 
polysaccharide/protein secretion profiles. It is also important to note that the compound 
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may be interfering with biofilm formation indirectly, such as by affecting signaling or 
quorum sensing pathways necessary for the initiation of the biofilm lifestyle. 
 
4.3 Evaluation of the mechanism of action of anti-biofilm compound T315 
 Gaining understanding of the mechanism of action of T315 has been attempted 
via multiple approaches and is an ongoing effort. First, generation of a T315-resistant S. 
Typhimurium isolate was attempted with the goal of performing whole-genome 
sequencing on this isolate to identify genetic loci altered from the wild-type which allow 
the bacterium to persist in biofilm formation in the presence of T315. Exposure of 
biofilm-residing S. Typhimurium to repeated and stepwise increasing doses of T315 
failed to generate an isolate with lasting resistance to the anti-biofilm agent. Upon 
increasing T315 dosage from 5 to 7.5 µM, initially observed “resistant” mutants did not 
retain this resistance. The idea of performing this process with a mutagenic S. 
Typhimurium strain to increase probability of a desirable mutation was considered, but 
ultimately not performed due to the challenges associated with evaluating individual 
contributions of a high number of genetic mutations to the T315-resistant phenotype 
within an obtained isolate.  
 Our ongoing approach to determine the mechanism of action of T315 is a direct 
pull-down of biotinylated T315 with its S. Typhimurium cellular targets. A polyethylene 
glycol (PEG) linker has been added to T315 at the site of the piperazine functional group 
via click chemistry, but analysis of this molecule indicates that the PEG addition at this 
site is detrimental to T315’s functionality. Our collaborators in the lab of Jim Fuchs are 
currently working to synthesize T315 with a PEG addition at the site of the amide (T315-
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PEG-ii). Once this molecule is synthesized, it will be evaluated to confirm that the PEG 
addition does not interfere with anti-biofilm activity of T315. Following this 
confirmation, a biotin marker will be added onto the PEG linker portion of T315-PEG-ii, 
and biotinylated T315 will be exposed to S. Typhimurium cellular lysate before utilizing 
biotin-streptavidin interactions to pull down T315 binding partners. Binding partners will 
be identified via mass spectrometry. 
  
4.4 Conclusions and Future Directions 
As a human-restricted pathogen, the carrier state of S. Typhi infection is 
fundamental to the spread of bacteria to new hosts and of consequential disease. The 
biofilm lifestyle within the gall bladder of carriers is an important aspect of chronic 
carriage that contributes to difficulties eradicating the spread of Salmonella. Used in 
conjunction with antibiotic therapy, anti-biofilm agents could be a useful therapeutic tool 
to limit chronic carriage and thus new S. Typhi infections. 
The stability of T315 and Cp315 within solution has been a limitation of this 
study. The compounds should be stored dry and not exposed to light for long-term 
storage. Stock solutions should be prepared in dimethyl sulfoxide (DMSO) and stored at  
-20°C, as the compounds are most soluble in DMSO. However, concentrations of DMSO 
greater than 1% in solution is toxic to Salmonella, so these compounds must be diluted in 
1x PBS directly before being administered. We believe this step of transfer into 1x PBS is 
the source of solubility issues and high variation of compound effectiveness between 
assays. Especially at concentrations over 10 µM, T315 is prone to precipitating out of 
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solution, which limited our EC50 studies to a narrow concentration range, as previously 
described. 
T315 is currently being derivatized to produce potential anti-biofilm compounds 
with a lower EC50 and/or greater solubility in 1x PBS. A scheme for this derivitization is 
depicted in Figure 10. Once synthesized, these compounds will be screened for biofilm 
inhibition against S. Typhimurium 14028s. Studies towards the discovery of the 
mechanism of action of T315 will be continued once the synthesis of T315-PEG-ii has 
been achieved. Once synthesized, T315-PEG-ii will be evaluated for preservation of anti-
biofilm activity to ensure that drug interactions have not been compromised by the 
addition of the polyethylene glycol linker. T315-PEG-ii will then be biotinylated, and this 
biotinylated compound will be utilized for direct pull down of T315 targets, which will 
be identified by mass spectrometry. Understanding the mechanism of action of T315 may 
provide novel insight into the Salmonella biofilm formation processes as well as direct 
future methods of synthesis of anti-biofilm agents to achieve diminution of the typhoid 
carrier state. 
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Tables 
 
 
 
 
 
 
 
 
 
 
Strain Characteristics Reference 
JSG210 S. Typhimurium ATCC 14028s (CDC6516-60); wild 
type 
ATCC 
JSG1547 JSG210 motA595::Tn10 Gift of T. Lino 
JSG1169 S. Typhimurium SR11x4252 Gift of A. Baumler 
JSG1174 JSG1169 Δ[fim-aph-11::Tn10]-391 lpfC::Kan 
pefC::Tet agfB::Cam 
Gift of A. Baumler 
JSG1178 JSG210 BC117 hin108::Tn10dCam (FljB off) Gift of B. Cookson 
JSG1179 JSG210 BC119 fliC::Tn10 hin108::Tn10dCam  (FljB 
on) 
Gift of B. Cookson 
JSG3736 JSG210 ΔcsgA via Wanner Adcox, et al. [13]	
 
JSG3828 A. baumannii 19606 Gift of D. Wozniak 
JSG3906 P. aeruginosa PAO1 Gift of D. Wozniak 
 
Table 1. Bacterial strains and relevant characteristics.  
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Figures 
 
 
 
 
 
 
Figure 1. Phases of biofilm development. "Biofilms: Multicellular Microbes?" [14]. 
The biofilm lifecycle is initiated via attachment of planktonic microorganisms to a 
surface in formation of a monolayer. The formation of microcolonies correlates with 
changes in gene expression to transition to biofilm lifecycle, such as down-regulation of 
motility genes, and precedes secretion of exopolysaccharide/extrapolymeric substance 
(EPS). Mature biofilms form characteristic biofilm towers encased in EPS, and are 
recalcitrant to immune and antimicrobial clearance. Return of biofilm members to 
planktonic state may be facilitated by passive detachment or active dispersal. 
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Figure 2. Chemical structure of T315. Regions of structural similarity between T315 
and Cp315 are depicted in black while regions of dissimilarity between the compounds 
are depicted in red.  
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Figure 3. Viability assays of S. Typhimurium in presence of 5 µM T315 and Cp315. 
Results indicate that reduction of biofilm observed in Rapid Attachment Assays was not 
due to bacteriostatic or bactericidal effects of T315 or Cp315, as the growth curves 
observed in presence of each drug are not markedly different from those without drug. 
This experiment was performed once. 
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Figure 4. (a) Effects of delayed drug delivery on biofilm formation. Biofilms were 
visualized via crystal violet assay 24h post final drug addition (5 µM). T315 on left panel, 
Cp315 on right panel. Early Addition Dispersion Assays utilized a similar methodology 
to Rapid Attachment Assays, but delayed delivery of drug to T=1, 3, and 6h post initial 
incubation. Results indicate that delivery of drug at T=1 and T=3 significantly decrease 
biofilm formation in both drugs, and delivery at T=6 significantly decreases biofilm 
formation in Cp315 only. Shown are results from one assay performed in 8 technical 
replicates. ***p<0.001  (b) Average percent inhibition of biofilm observed under delayed 
drug delivery using results from three biological replicates. ***p<0.001, **p<0.01, 
*p<0.05 
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Figure 5. Half maximal effective concentration (EC50) determination of T315. 
Determination of the half-maximal effective concentration of T315 was achieved by 
exposing JSG210 to drug concentrations from 0.5 to 9 µM and examining the levels of 
subsequent anti-biofilm activity after 24h via crystal violet staining technique. The EC50  
was determined to be  4.61 µM with a 95% confidence interval from 3.13 to 6.78 µM. 
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Figure 6. Evaluation of T315 anti-biofilm effects on P. aeruginosa (JSG3906) and A. 
baumannii (JSG3828). (a) After 24h exposure of 10 µM T315, JSG3828 biofilm 
formation was reduced by an average of 61.2%, quantified via crystal violet assay. 
Exposure of JSG3906 to 5 µM T315 did not significantly affect biofilm formation after 
24h. ***p<0.001. (b) Enumeration of viable JSG3828 at timepoints over 24h exposure to 
10 µM T315 suggests that anti-biofilm activity is not a resultant of bacteriostatic or 
bactericidal effects. This assay was performed once. 
 
 
 
a. 
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Figure 7. T315-related compounds Cp315 and In-T315 effects on S. Typhimurium 
biofilm formation. 24h crystal violet assays indicate that both Cp315 and In-T315 
significantly inhibit biofilm formation of JSG210 at 5 µM, by 58.4% and 78.4%, 
respectively. In-T315 was seen to inhibit biofilm formation at 10 µM.by 83.3%. 
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Figure 8. Evaluation of T315 anti-biofilm activity against S. Typhimurium flagella 
curli fimbriae, and motility mutants. Biofilm formation of each bacterial strain with 
and without the presence of 5 and 10 µM T315 was quantified after 24h by crystal violet 
staining. These data were used to compute percent inhibition of biofilm formation caused 
by the compound, shown above. (a) JSG1178 was seen to experience an average percent 
inhibition of biofilm formation significantly different than the wild type JSG210 
background strain when exposed to 10 µM T315. In these studies, JSG1178 exposed to 
10 µM T315 exhibited 58.9% inhibition of biofilm formation while JSG210 exhibited 
78.4%. p<0.05. (b) No significant difference between T315-induced biofilm inhibition 
was observed between JSG1174 fimbriae mutant and JSG1169 SR11 wild type 
background. 
a. 
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Figure 9. (a) Structure of T315-PEG-i. Sites of polyethylene glycol linker attachment for 
T315-PEG-i and T315-PEG-ii are indicated in blue. (i) pyrazole, (ii) amide site. (b) Loss 
of biological activity of T315-PEG-i. 24h drug exposure followed by crystal violet 
staining indicates that T315-PEG-i does not significantly reduce biofilm formation of S. 
Typhimurium at 5 or 10 µM concentrations.  
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Figure 10. Scheme for the derivatization of key functional moieties of T315 based on 
the established synthesis of T315 and related analogues for cancer screening. 
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